Abstract
Background
Identification of positive biomarkers for the effects of nivolumab on patients with advanced gastric cancer (AGC) is significant. The Gustave Roussy Immune Score (GRIm-s) is associated with therapeutic resistance of immune checkpoint inhibitors (ICIs) in other cancers. This multicenter, retrospective study was designed to analyze the association of GRIm-s with therapeutic sensitivity of nivolumab in patients with AGC.
Methods
We reviewed 58 patients with AGC treated with nivolumab from October 2017 to November 2018 at five participating institutions. We performed blood tests before the start of nivolumab and after administration of two courses. We evaluated the correlation between the best overall response and GRIm-s. Additionally, we focused on the changes in GRIm-s before the start of nivolumab and after administration of two courses.
Results
Of the 58 patients, 21 (36.2%) were classified into the disease control (DC) group and 37 (63.8%) into the progressive disease (PD) group. GRIm-s before nivolumab treatment did not correlate with the best therapeutic response (p = 0.086). However, GRIm-s after two courses of nivolumab showed that significantly more PD cases were in the high-risk group (p < 0.0001). After two courses of nivolumab, overall survival was significantly worse in the high-risk group (p < 0.0001). For progression-free survival, the high-risk group had a significantly worse prognosis both before (p = 0.04) and after two courses of nivolumab treatment (p < 0.0001).
Conclusions
GRIm-s after two courses of nivolumab and its changes compared to pretreatment values proved beneficial in predicting nivolumab sensitivity.
Similar content being viewed by others
References
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics. CA Cancer J Clin. 2015;65:87–108. https://doi.org/10.3322/caac.21262.
Yamashita K, Sakuramoto S, Nemoto M, et al. Trend in gastric cancer: 35 years of surgical experience in Japan. World J Gastroenterol. 2011;17:3390–7. https://doi.org/10.3748/wjg.v17.i29.3390.
Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461–71. https://doi.org/10.1016/S0140-6736(17)31827-5.
Janjigian YY, Shitara K, Moehler M, et al. Nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/oesophageal adenocarcinoma (CheckMate 649): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;398:27–40. https://doi.org/10.1016/S0140-6736(21)00797-2.
Ito S, Masuda T, Noda M, et al. Prognostic significance of PD-1, PD-L1 and CD8 gene expression levels in gastric cancer. Oncology. 2020;98:501–11. https://doi.org/10.1159/000506075.
Wu Y, Cao D, Qu L, et al. PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer. Oncotarget. 2017;8:64066–82.
Shin HM, Kim G, Kim S, et al. Chromatin accessibility of circulating CD8 + T cells predicts treatment response to PD-1 blockade in patients with gastric cancer. Nat Commun. 2021;12:975. https://doi.org/10.1038/s41467-021-21299-w.
Wang F, Wei XL, Wang FH, et al. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432. Ann Oncol. 2019;30:1479–86. https://doi.org/10.1093/annonc/mdz197.
Choi E, Chang MS, Byeon SJ, et al. Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas. Diagn Pathol. 2020;15:69. https://doi.org/10.1186/s13000-020-00979-z.
McLaughlin J, Han G, Schalper KA, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol. 2016;2:46–54. https://doi.org/10.1001/jamaoncol.2015.3638.
Nakazawa N, Sohda M, Yamaguchi A, et al. An elevated serum lactate dehydrogenase-to-albumin ratio is a useful poor prognostic predictor of nivolumab in patients with gastric cancer. Anticancer Res. 2021;41:3925–31.
Ota Y, Takahari D, Suzuki T, et al. Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival. Cancer Chemother Pharmacol. 2020;85:265–72. https://doi.org/10.1007/s00280-019-04023-w.
Bigot F, Castanon E, Baldini C, et al. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: the Gustave Roussy Immune Score (GRIm-Score). Eur J Cancer. 2017;84:212–8. https://doi.org/10.1016/j.ejca.2017.07.027.
Minami S, Ihara S, Ikuta S, Komuta K. Gustave Roussy immune score and Royal Marsden Hospital prognostic score are biomarkers of immune-checkpoint inhibitor for non-small cell lung cancer. World J Oncol. 2019;10:90–100.
Aldea M, Benitez JC, Mezquita L. The Lung Immune Prognostic Index (LIPI) stratifies prognostic groups in advanced non-small cell lung cancer (NSCLC) patients. Transl Lung Cancer Res. 2020;9:967–70.
Lenci E, Cantini L, Pecci F, et al. The Gustave Roussy Immune (GRIm)-score variation is an early-on-treatment biomarker of outcome in advanced non-small cell lung cancer (NSCLC) patients treated with first-line pembrolizumab. J Clin Med. 2021;10:1005. https://doi.org/10.3390/jcm10051005.
Sano A, Sohda M, Nakazawa N, et al. Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective study. BMC Cancer. 2022;22:22. https://doi.org/10.1186/s12885-021-09118-3.
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009. https://doi.org/10.1007/s12325-020-01229-w.
Russo A, Russano M, Franchina T, et al. Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and outcomes with nivolumab in pretreated non-small cell lung cancer (NSCLC): A large retrospective multicenter study. Adv Ther. 2020;37:1145–55. https://doi.org/10.1007/s12325-020-01229-w.
Capone M, Giannarelli D, Mallardo D, et al. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. J Immunother Cancer. 2018;6:74. https://doi.org/10.1186/s40425-018-0383-1.
Tachinami H, Tomihara K, Ikeda A, et al. Neutrophil-to-lymphocyte ratio (NLR) as a predictive indicator of the response to nivolumab in patients with oral squamous cell carcinoma. Gan To Kagaku Ryoho. 2021;48:1485–90.
Ueda T, Chikuie N, Takumida M, et al. Baseline neutrophil-to-lymphocyte ratio (NLR) is associated with clinical outcome in recurrent or metastatic head and neck cancer patients treated with nivolumab. Acta Oto-Laryngol. 2020;140:181–7. https://doi.org/10.1080/00016489.2019.1699250.
Ota Y, Takahari D, Suzuki T, et al. Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival. Canc Chemother Pharmacol. 2020;85:265–72. https://doi.org/10.1007/s00280-019-04023-w.
Wu CY, Wu MS, Chiang EP, et al. Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut. 2007;56:782–9. https://doi.org/10.1136/gut.2006.109868.
Middleton K, Jones J, Lwin Z, Coward JI. Interleukin-6: an angiogenic target in solid tumours. Crit Rev Oncol Hematol. 2014;89:129–39. https://doi.org/10.1016/j.critrevonc.2013.08.004.
Ock CY, Nam AR, Lee J, et al. Prognostic implication of antitumor immunity measured by the neutrophil–lymphocyte ratio and serum cytokines and angiogenic factors in gastric cancer. Gastric Cancer. 2017;20:254–62. https://doi.org/10.1007/s10120-016-0613-5.
Motomura T, Shirabe K, Mano Y, et al. Neutrophil–lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol. 2013;58:58–64. https://doi.org/10.1016/j.jhep.2012.08.017.
Aday U, Tatlı F, Akpulat FV, et al. Prognostic significance of pretreatment serum lactate dehydrogenase-to-albumin ratio in gastric cancer. Contemp Oncol (Pozn). 2020;24:145–9. https://doi.org/10.5114/wo.2020.100219.
Taniguchi Y, Tamiya A, Isa SI, et al. Predictive factors for poor progression-free survival in patients with non-small cell lung cancer treated with nivolumab. Anticancer Res. 2017;37:5857–62.
Agulló-Ortuño MT, Gómez-Martín Ó, Ponce S, et al. Blood predictive biomarkers for patients with non-small-cell lung cancer associated with clinical response to nivolumab. Clin Lung Cancer. 2020;21:75–85. https://doi.org/10.1016/j.cllc.2019.08.006.
Roche M, Rondeau P, Singh NR, Tarnus E, Bourdon E. The antioxidant properties of serum albumin. FEBS Lett. 2008;582:1783–7. https://doi.org/10.1016/j.febslet.2008.04.057.
Feng JF, Wang L, Yang X, Chen S, Score GRI. Gustave Roussy Immune Score (GRIm-Score) is a prognostic marker in patients with resectable esophageal squamous cell carcinoma. J Cancer. 2020;11:1334–40. https://doi.org/10.7150/jca.37898.
Acknowledgments
The authors thank Ms. Harumi Kanai for her excellent assistance. The authors have no conflicts of interest to declare and disclose no grant support.
Funding
The authors disclose no grant support.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosure
The authors have no conflict of interest to declare.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Nakazawa, N., Sohda, M., Ubukata, Y. et al. Changes in the Gustave Roussy Immune Score as a Powerful Prognostic Marker of the Therapeutic Sensitivity of Nivolumab in Advanced Gastric Cancer: A Multicenter, Retrospective Study. Ann Surg Oncol 29, 7400–7406 (2022). https://doi.org/10.1245/s10434-022-12226-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-022-12226-4